TipRanks
Go Ultimate55% OFF

Compare Knight Therapeutics (KHTRF) vs. Competitors

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
KHTRFKnight Therapeutics$8.13$791.17M76.9595.43%Strong BuyUnlock the KHTRF analyst price target with TipRanks PremiumKHTRFUnlock the KHTRF top-analyst price target with TipRanks Premium
TSE:CPHCipher PharmaceuticalsCAD 13.39CAD 331.67M8.28-10.81%Moderate BuyUnlock the TSE:CPH analyst price target with TipRanks PremiumKHTRF vs TSE:CPHUnlock the TSE:CPH top-analyst price target with TipRanks Premium
TSE:OGIOrganigram GlobalCAD 1.36CAD 186.13M2.12-40.09%Moderate BuyUnlock the TSE:OGI analyst price target with TipRanks PremiumKHTRF vs TSE:OGIUnlock the TSE:OGI top-analyst price target with TipRanks Premium
TSE:ACBAurora CannabisCAD 5.95CAD 372.12M-3.05-15.37%Moderate BuyUnlock the TSE:ACB analyst price target with TipRanks PremiumKHTRF vs TSE:ACBUnlock the TSE:ACB top-analyst price target with TipRanks Premium
TSE:CRONCronos GroupCAD 4.72CAD 1.70B17.8933.14%Moderate BuyUnlock the TSE:CRON analyst price target with TipRanks PremiumKHTRF vs TSE:CRONUnlock the TSE:CRON top-analyst price target with TipRanks Premium
TSE:HLSHLS Therapeutics IncCAD 4.58CAD 139.52M-12.23-19.89%Moderate BuyUnlock the TSE:HLS analyst price target with TipRanks PremiumKHTRF vs TSE:HLSUnlock the TSE:HLS top-analyst price target with TipRanks Premium

Performance Comparison

-50%-25%0%25%50%75%100%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
KHTRFKnight Therapeutics8.133.9795.48%
TSE:CPHCipher Pharmaceuticals13.20-1.54-10.45%
TSE:OGIOrganigram Global1.36-0.84-38.18%
TSE:ACBAurora Cannabis5.89-0.97-14.14%
TSE:CRONCronos Group4.701.1432.02%
TSE:HLSHLS Therapeutics Inc4.47-1.03-18.73%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts